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Abstract
Background:  MB2 protein is a sporozoite surface antigen on the human malaria parasite
Plasmodium falciparum. MB2 was identified by screening a P. falciparum sporozoite cDNA expression
library using immune sera from a protected donor immunized via the bites of P. falciparum-infected
irradiated mosquitoes. It is not known whether natural exposure to P. falciparum also induces the
anti-MB2 response and if this response differs from that in protected individuals immunized via the
bites of P. falciparum infected irradiated mosquitoes. The anti-MB2 antibody response may be part
of a robust protective response against the sporozoite.
Methods: Fragments of polypeptide regions of MB2 were constructed as recombinant fusions
sandwiched between glutathione S-transferase and a hexa histidine tag for bacterial expression. The
hexa histidine tag affinity purified proteins were used to immunize rabbits and the polyclonal sera
evaluated in an in vitro inhibition of sporozoite invasion assay. The proteins were also used in
immunoblots with sera from a limited number of donors immunized via the bites of P. falciparum
infected irradiated mosquitoes and plasma and serum obtained from naturally exposed individuals
in Kenya.
Results: Rabbit polyclonal antibodies targeting the non-repeat region of the basic domain of MB2
inhibited sporozoites entry into HepG2-A16 cells in vitro. Analysis of serum from five human
volunteers that were immunized via the bites of P. falciparum infected irradiated mosquitoes that
developed immunity and were completely protected against subsequent challenge with non-
irradiated parasite also had detectable levels of antibody against MB2 basic domain. In contrast, in
three volunteers not protected, anti-MB2 antibodies were below the level of detection. Sera from
protected volunteers preferentially recognized a non-repeat region of the basic domain of MB2,
whereas plasma from naturally-infected individuals also had antibodies that recognize regions of
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MB2 that contain a repeat motif in immunoblots. Sequence analysis of eleven field isolates and four
laboratory strains showed that these antigenic regions of the basic domain of the MB2 gene are
highly conserved in parasites obtained from different parts of the world. Moreover, anti-MB2
antibodies also were detected in the plasma of 83% of the individuals living in a malaria endemic
area of Kenya (n = 41).
Conclusion: A preliminary analysis of the human humoral response against MB2 indicates that it
may be an additional highly conserved target for immune intervention at the pre-erythrocytic stage
of P. falciparum life cycle.
Background
Parasites of the Plasmodium species that are transmitted to
people through the bites of infected mosquitoes cause
malaria, a life-threatening disease. Malaria poses a serious
public health problem in many parts of the world and
approximately half of the world's population is at risk, in
particular those living in lower-income countries [1]. The
four types of human malaria are caused by Plasmodium fal-
ciparum, Plasmodium vivax, Plasmodium malariae and Plas-
modium ovale. Of these, P. falciparum and P. vivax are the
most common and P. falciparum is the most deadly [1].
Emergence of drug and insecticide resistance has exacer-
bated the situation, undermining the effectiveness of
existing malaria control methods that depend on chemo-
therapy and vector control, respectively. Clearly, addi-
tional effective means to fight the disease, such as a safe
and effective vaccine(s) are needed urgently. Currently,
several approaches to developing malaria vaccine are in
various stages of pre-clinical and clinical development
involving single and multi-stage targets these are dis-
cussed in depth elsewhere [2-6].
Successful vaccination of humans on a limited scale
against P. falciparum malaria was achieved first using irra-
diated sporozoites as an immunogen [7]. This approach
follows the classical route of vaccine development via
attenuation; in this case radiation induced attenuation
resulting in non-replicating metabolically-active P falci-
parum sporozoites and results in targeting the pre-erythro-
cytic stage. This type of vaccine has to be 100% effective to
induce sterile protective immunity and prevent the devel-
opment of blood-stage infection in naïve individuals.
Other vaccine candidates targeting the pre-erythrocytic
stage that are less than 100% effective, may not prevent,
but delay the onset of disease in naïve individuals and
reduce subsequent episodes of clinical malaria [8], and as
such may still play an important role in the fight against
malaria. Although non-replicating metabolically-active
sporozoites as immunogen(s) appears to be effective and
the limited data are encouraging, the development of this
approach leading to a licensed product for the prevention
of malaria infection presents challenges and opportuni-
ties [9]. As efforts continue to develop this potential pre-
erythrocytic stage attenuated vaccine, the volunteers that
have already participated in the early phases of validation
warrant further evaluation to examine the nature of this
induced sterile protective response with a view to identify-
ing key responsive elements to provide insights into the
molecular basis of this immunity.
The pre-erythrocytic immune response is primarily
directed against the circumsporozoite (CS) protein, a sur-
face protein of Plasmodium sporozoites [10-12]. The CS
protein is a leading vaccine candidate because irradiated
sporozoite-induced protection in volunteers correlates
with high circulating levels of anti-CS antibodies [13], and
these antibodies are directed against the immunodomi-
nant B cell epitopes in the central tetramer repeat [Aspar-
agine Proline Asparagine Alanine]n (NPNA)n. Moreover a
human monoclonal antibody directed against CS protein
(NPNA)n tetramer repeat isolated from a protected indi-
vidual immunized via bites of infected, irradiated mos-
quitoes and subsequently shown to be protected against
non-irradiated parasite challenge exhibited dose-depend-
ent inhibition of P. falciparum sporozoites invasion of
HepG2-A16 cells in vitro [14,15]. Recent attempts to
induce protection in humans using P. falciparum CS-based
vaccines containing the NPNA repeat motif, with
improvement in their immunogenicity, and formulation,
such as RTS, S/AS02 have yielded promising results [16].
To induce the protective immunity that is as consistent
and long-lasting as that observed in the irradiated-sporo-
zoite exposed individuals may require a vaccine that not
only targets additional sporozoites surface antigens, but
also provides a mechanism for extended priming of the
immune system. The later present significant challenges in
vaccine delivery and short of radiation or genetically-
attenuated non-replicating metabolically-active sporo-
zoite, may be difficult to mimic. However, in addition to
the immunodominant CS protein it may be important to
identify antigens that may act independently, additively
or synergistically and contribute towards more robust pro-
tection. To-date several candidate molecules, including
thrombospondin-related anonymous protein
(TRAP)[17], also know as sporozoite surface protein 2
(SSP2)[18], sporozoite-threonine-asparagine-rich protein
(STARP)[19] and the more recently identified MB2 [20],
have been shown to be present on the sporozoite surface.Malaria Journal 2009, 8:235 http://www.malariajournal.com/content/8/1/235
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The P. falciparum gene MB2, is a single copy gene on chro-
mosome five, and is expressed as a single mRNA transcript
in erythrocytic stage of parasites, the predicted transla-
tional product is 1610 amino acids in length with a pre-
dicted mass of 187 kDa. The translated primary sequence
may be further subdivided into three domains, an amino
terminal basic domain, a central acidic domain and a car-
boxyl terminal domain with high sequence similarity to
GTP-binding domains. The MB2  gene products are
present in the sporozoite, asexual blood stages and game-
tocytes and have a distinct pattern of stage dependent sub-
cellular localisation and proteolytic processing at the var-
ious stages of the parasite life cycle[20]. To-date gene
homologues to the P. falciparum MB2, (PfMB2) have been
identified in Plasmodium knowlesi(PkMB2), Plasmodium
gallinaceum (PgMB2), Plasmodium berghei (PbMB2), Plas-
modium yoelii (PyMB2), Plasmodium chabaudi (PcMB2)
[21] and P. vivax(PvMB2) (GenBank Accession
XM_001613742). Of four conserved regions of the puta-
tive  MB2  translation products, two have similarity to
known proteins, S1 domain involved in initiation of
translation and mRNA turnover and a GTP-binding
domain similar to the family G-domains involved in pro-
tein synthesis [21]. In the non-conserved region of PfMB2,
PyMB2 and PgMB2 tandemly repeated amino acid motifs
are present. Repeat motifs are present in other malarial
surface proteins including CS, TRAP and merozoite sur-
face proteins (MSP) [22]. These repetive regions are T-cell
independent repeat regions of parasite antigen and it has
been postulated that the immune response against these
regions diverts the response away from more important
epitopes [23].
The MB2 antigen possesses intriguing immunogenic and
molecular properties that indicate that it may be an
important immune target in the non-replicating metabol-
ically active P. falciparum sporozoite attenuated vaccine
and may complement and enhance the efficacy of pre-
erythrocytic stage vaccines currently in development.
Methods
Recombinant protein expression and purification
Fragments of the MB2 open reading frame were expressed
in bacteria as Glutathione-S-Transferase (GST)-MB2-
6xHistidine (His) fusion proteins in the dual-affinity
pAK1-6H expression vector [24]. The oligonucleotide
primers used to construct the GST-MB2-6xHis recom-
binant proteins are listed in Table 1. The cloning of MB2
fragments into the expression vector was described in ear-
lier studies [20]. Purification of recombinant proteins was
carried out using the ProBond resin (Invitrogen) with the
addition of imidazole at 85 mM final concentration in the
Table 1: Names, positions, and sequences of oligonucleotide primers used to clone and express GST-fusion proteins representing 
various regions of the MB2 open reading frame.
GST-fusion Amino acida
MB2-A
5' primer-Nco I b(98)GATGCCATGGGTGTTAATAGATGTTTTAC
3' primer-Sma I (305)GATCCCGGGGAGCATATTCTATTATATTCA 32 - 101
MB2-B
5' primer-Nco I (286)GATGCCATGGAATATAATAGAATATGCA
3' primer-Sma I (620)GATCCCGGGTTTTTATTATTAGAAGAATCA 95 - 206
MB2-Cc
5' primer-Nco I (602)GATGCCATGGATTCTTCTAATAATAAAAT
3' primer-Sma I (953)ATGCATCCCCGGGTCATTTTTTATTTGAAGAATTCTC 200- 316
MB2-Fd
5' primer-Nco I (98)GATGCCATGGGTGTTAATAGATGTTTTATC
3' primer-Sma I (953)ATGCATCCCCGGGTCTTTTTTATTTGAAGAATTCTC 32 - 316
MB2-D
5' primer-Nco I (1066)GATGCCATGGCATCTACATTAGATGAAACA
3' primer-Sma I (1640)GATCCCGGGGATGTACTATAATCATTATTTGG 355 - 546
MB2-E
5' primer-Nco I (1616)GATGCCATGGATCCAAATAATGATTATAGTACA
3' primer-Sma I (2321)GATCCCGGGCTTGAATTATATTCTTTATTTTCGTG 538 - 773
MB2-FAc
5' primer-Nco I (2294)GTATGCCATGGTCCACGAAAATAAAGAATATAATTCAAG
3' primer-Sma I (2837)GATCCCGGGTCATCGAGCGATTCATTTTGGTC 764 - 945
MB2-IF2
5' primer-Nco I (4009)GATGCCATGGATGGTAATAGAACAAATAATGAC
3' primer-Sma I (4823)GATCCCGGGTACGCTTCGATTATATCGTTTGGCTC 1337 - 1606
a Numbers indicate amino acid positions relative to the initiation methionine (1), b Numbers in parenthesis refer to nucleotide positions relative to 
the ATG initiation codon; bold underlined letters indicate the restriction endonuclease sites, Nco I and Sma I,c These peptides includes amino acid 
repeats, d This peptide is a combination of MB2-A, -B, and -C.Malaria Journal 2009, 8:235 http://www.malariajournal.com/content/8/1/235
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washing buffer. Eluted fractions were analysed by SDS-
PAGE and immunoblotting using anti-GST antibodies.
Human plasma and serum
Samples of plasma were obtained from individuals living
in an area of Kenya with highly seasonal malaria transmis-
sion. Samples were obtained during high transmission
season from individuals two years of age or older. Plasma
donors were assessed for symptoms of malaria and the
presence of P. falciparum parasitaemia on microscopic
examination of peripheral blood smears. Of the forty-one
plasma donors, nine were smear negative, seven were
smear positive but asymptomatic, and twenty-five were
smear positive and symptomatic. Symptomatic individu-
als had one or more of the following symptoms: fever,
chills, headache, severe malaise or vomiting. Samples
with available serum were tested for antibodies to CSP
and TRAP by ELISA, as described previously [25]. Levels
were given in arbitrary units (AU). The AU was deter-
mined by dividing the optical density (OD) of the study
sample by the mean plus three standard deviations of the
ODs of nine North American control sera. The cut-off for
a positive response was an AU of 1. Informed consent was
obtained from all individuals and their guardians, as
described previously [26]. Ethical approval was obtained
from the Ethical Review Committee at the Kenya Medical
Research Institute and the Human Investigations Institu-
tional Review Board at Case Western Reserve University
and the University Hospital of Cleveland.
Samples of serum from eight volunteers experimentally
immunized by the bites of irradiated, infected mosquitoes
were obtained from W.O. Rogers at the US Naval Medical
Research Center (Rockville, Maryland); and from U.
Krzych at the Walter Reed Army Institute of Research
(Washington DC). Upon challenge with bites of P. falci-
parum  infected, non-irradiated mosquitoes out of the
eight volunteers five were completely protected (W. Rog-
ers and U. Krzych, personal communication).
Immunoblot analyses
Purified GST-MB2 recombinant proteins (~50-100 ng)
were resolved by SDS-PAGE in a 12% polyacrylamide gel
and transferred onto a nitrocellulose membrane. The
membrane was incubated with the human plasma or
serum diluted 1:100 in Tris-buffered saline (TBS) + 0.05%
Tween-20 (TBST) for two hours at room temperature. Fol-
lowing washing with TBST, the filters were incubated in
HRP-conjugated anti-human IgG (CalBiochem, San
Diego, CA) diluted 1:80,000 in TBST and the enhanced
chemiluminescence (ECL) system (Amersham Bio-
sciences Corp, Piscataway, NY) used for detection. Rabbit
anti-GST antibodies were used as a positive control and
normal human serum was used as a negative control.
Amplification and sequence of MB2 genes from diverse 
parasite populations
Plasmodium falciparum genomic DNA extracted from labo-
ratory-maintained strains and field isolates from infected
red blood cells was kindly provided by Dr. A. Lal, (Centers
for Disease Control and Prevention, Atlanta). The nucle-
otides encoding the antigenic region of the B domain of
MB2  (aa 1-317 amino acids) were amplified from
genomic DNA by the polymerase chain reaction (PCR)
using the following primers: 5'-ATGTTTCTAATAT-
GGCGTTTG-3' and 5'-TCATTTTTATTTGAAGAATT-3'.
Conditions for amplification included an initial DNA
denaturation of 94°C for 2 min, followed by 30 cycles at
94°C for 20 s, 55°C for 20 s, and 60°C for 1 min.
Genomic DNA (200 ng) of each lab strain was used as
template in the reaction. The concentration of genomic
DNA of field isolates used as template in the amplification
reaction is not known due to the limited quantity of the
sample. The amplification products were cloned into a TA
cloning vector using the TOPO-PCR cloning kit (Invitro-
gen). Plasmid DNA was prepared from bacterial cultures
and the inserts sequenced in both directions. Cloning and
sequencing were repeated on amplification products
obtained independently to ensure reproducibility of the
sequence data. Alignment of the sequences was performed
by the Clustal method using the Megalign program from
the Lasergene computer software.
Rabbit immunization and total IgG purification
Rabbit immunization procedures used to obtain polyclo-
nal antibodies against MB2 recombinant proteins are
described elsewhere [20]. For IgG purification, the Immu-
noPure® IgG Protein A purification kit was used following
the protocol provided by the manufacturer (Pierce, Rock-
ford, IL).
In vitro inhibition of sporozoite invasion (ISI) assay
To determine whether antibody targeting a particular
domains or sub domains of MB2 had an effect on the abil-
ity of sporozoites to enter hepatocytes, total purified IgG
from sera obtained from rabbits immunized against three
different regions of MB2 (MB2-B, -C, and -FA) and a pos-
itive control NFS1 monoclonal antibody [27] were used
in ISI assays of cultured liver cells [28,29]. A human
hepatoma cell line, HepG2-A16, [28] was used for the
assay. Briefly 50,000 HepG2-A16 cells were seeded on
eight-chamber plastic Lab-Tek slides (Miles Research) in
supplemented minimal essential medium (MEM) as
described [28]. The purified antibodies were added to a
final concentration of 100 g/ml, and HepG2-A16 cells
were infected with 25,000 P. falciparum NF54 sporozoites.
Slides were incubated at 37°C in 5% CO2 for three hours,
washed twice with phosphate-buffered saline (PBS), fixed
with cold methanol, and rinsed twice again with PBS. Spo-
rozoites that had invaded hepatoma cells were visualizedMalaria Journal 2009, 8:235 http://www.malariajournal.com/content/8/1/235
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by phase-contrast light microscopy using immunohisto-
chemical staining with a mouse monoclonal antibody
(NFS1) [27] against P. falciparum CS protein. Slides were
incubated with NFS1 (10 g/ml) for 30 min at room tem-
perature, followed by goat anti-mouse IgG peroxidase
conjugate for 30 min at room temperature. The ISI assays
were done in triplicate with pre-immune IgG used as the
negative control and the anti-CS monoclonal antibody
NFS1 used as the positive control.
Results
Recombinant protein expression and purification
GST-MB2 recombinant proteins representing various
regions of the coding sequence of MB2 were expressed in
bacteria (Figure 1A). Bacteria transformed with plasmids
carrying different regions of MB2 required different induc-
tion times and culture media for optimal yield (Table 2).
The level of recovered protein varied greatly for each
recombinant construct. The inclusion of 80-85 mM imi-
dazole in the wash buffer and an overnight wash during
isolation were essential in improving the purity of the
recombinant proteins. All of the expressed proteins were
soluble and thus purified readily from the cell-free bacte-
rial lysates by one-step nickel column chromatography
and were readily detected in an immunoblot using rabbit
anti-GST antibodies (Figure 1B).
Immunoblot plasma and serum analyses
All smear negative donors were exposed previously to P.
falciparum as evidenced by the presence of anti-CS and
anti-TRAP antibodies in their plasma (Table 3). The
results of the immunoblot analyses obtained with the
serum from a protected volunteer (#5, Table 3) and
endemic plasma (KU162, Table 3), showed that both con-
tain antibodies against the basic domain and some resid-
ual antibody reactivity was observed against regions of the
acidic domain, whilst no antibody reactivity was detected
against the GTP binding domain fragment as shown in
Figure 1. Moreover, the regions of MB2 reacting with the
immune sera are limited to the central region of the basic
domain in particular MB2-B and MB2-C fragments. It
would appear that serum from this protected (#5) individ-
ual reacts preferentially with MB2-B (non-repeat contain-
ing) and to a lesser degree with the MB2-C (repeat
containing) region. In contrast the plasma from the
endemic (KU162) region appears to have the inverse reac-
Immunoblot analyses to assess the presence of antibody against MB2 recombinant peptides Figure 1
Immunoblot analyses to assess the presence of antibody against MB2 recombinant peptides. A, is a schematic 
representation of the MB2 protein sequence. The three domains, Basic (B), Acidic (A), and GTP-binding (G), are indicated 
as blocks with the amino acid junctions numbered below. The seven short horizontal lines represent the approximate extents 
of the polypeptides that were expressed as GST-fusion recombinant proteins. B, immunoblots of GST-MB2 recombinant pro-
teins reacted with anti-GST rabbit serum (Anti-GST); or serum of a protected volunteer (#5 volunteer); or serum of a per-
son living in a malaria-endemic area (Endemic serum #KU 162). Immunoblots were prepared in triplicate, and each lane 
contains 50-100 ng of purified GST-MB2 recombinant proteins. Recombinant proteins, MB2-C, MB2-D, and MB2-FA, listed in 
bold letters contain amino acid repeats. Approximate molecular weights of the fusion proteins are indicated in kilodaltons 
(kDa).
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tivity (i.e., MB2-C staining more strongly than MB2-B).
Moreover, the endemic plasma also contained antibodies
against the acidic domain fragments MB2-D and MB2-E.
The protected sera (#5) had no detectable antibody
against MB2-D, but some slight reactivity against MB2-E.
The initial immunoblot analysis showed that the pro-
tected volunteer (#5) serum recognized principally the
two regions in the basic domain, and these regions were
recognized differently by the endemic (KU 162) plasma.
To determine if this differential antibody recognition cor-
related with the different immunity observed between
protected volunteers and the status of intermittently-
exposed individuals living in area of seasonal transmis-
sion, the immunoblot analysis was expanded to include
plasma obtained from a total of forty one individuals liv-
ing in an area of seasonal malaria transmission who were
blood-smear negative for P. falciparum (n = 9), blood
smear positive but asymptomatic (n = 7) or blood smear
positive and symptomatic (n = 25). Serum samples from
eight irradiated sporozoite exposed volunteers, of which
five had acquired sterile immunity, were also included.
Results of the expanded immunoblot analyses of the basic
domain fragments MB2-A, -B and -C are summarized in
Table 3. A total of 83% (34/41) of naturally exposed indi-
viduals had antibodies against the basic domain of MB2
and prevalence against MB2-C and MB2-B was 78 and
61%, respectively. The prevalence of antibody against
MB2-B and -C in plasma from smear negative donors rel-
ative to smear positive donors was determined (MB2-B
89%, MB2-C 100%) and (MB2-B 53%, MB2-C 72%)
respectively. The overall prevalence of antibody response
against the repeat MB2-C region was greater than against
the non-repeat, MB2-B region. Comparison between
smear positive (n = 32) (parasitaemic) and smear negative
(n = 9) (non-parasitaemic) individuals for the presence of
antibody against MB2-B approaches significance (p =
0.066, Fisher's exact test). Minimal or no antibody reac-
tion was detected against the amino-terminal MB2-A
region. In comparison, the immunoblot result obtained
with sera of irradiated-sporozoite immunized volunteers
showed an association between the anti-MB2 antibody
response and the immune status of the volunteers (Table
3). The five protected volunteers produced anti-MB2 anti-
bodies that were directed preferentially against the non-
repeat MB2-B region. In contrast, all three unprotected
volunteers did not produce a detectable antibody
response against MB2.
All nine smear negative individuals had antibodies to CSP
and/or TRAP, demonstrating evidence of prior exposure
to P. falciparum (Table 3). As compared to smear negative
individuals, smear positive individuals who had plasma
available for testing for antibodies to CSP and TRAP by
ELISA had lower levels of antibodies to TRAP (smear pos-
itive, median AU 1.13, range 0.1 - 2.95, as compared to
smear negative, median AU 2.08, range, 1.17 - 4.8, P =
0.02) but not CSP (smear positive, median AU 1.06, range
0.3 - 3.01, as compared to smear negative, median
AU1.75, range, 0.55 - 4.28, P = 0.11). Smear positive indi-
viduals were also less frequently positive for antibodies to
CSP (14 of 26 individuals tested) or TRAP (15 of 26 indi-
viduals tested) (Table 3).
Polymorphism assessment of the antigenic region of the 
MB2 basic domain
The nucleotide sequence encoding the first 317 amino
acids of MB2 corresponding to the B-cell epitopes that
were recognized differentially in the immunoblot analysis
were determined. The nucleotide sequences have been
deposited in GenBank with accession numbers
AF454665, AF454666, AF454667, AF378132, AF378136
and XM_001351687. The translated amino acid sequence
alignment of the antigenic region of MB2 from four labo-
ratory strains and 11 field isolates collected from India (n
= 3), Venezuela (n = 4), Thailand (n = 3) and Papua New
Guinea (n = 1) show that the only variation observed is in
Table 2: Optimal conditions to express GST-MB2 recombinant polypeptides in E. coli.
Name Amino Acid Positiona (Size) Net Chargeb Mediac Induction Time Expression Leveld
MB2-A 32-101, (70 aa) +8.94 SB 1 hr 10 min 1-2 mg/L
MB2-B 95-206, (112 aa) +10.18 LB 8 hrs 3 mg/L
MB2-C 200-316, (117 aa) +2.58 LB 4 hrs 4 mg/L
MB2-Fe(A-B-C) 32-316, (285 aa) +21.91 SB 4 hrs 2 mg/L
MB2-D 355-546, (192 aa) -0.72 SB 1-6 hrs 0.1-0.2 mg/L
MB2-E 538-773, (236 aa) +8.23 SB 1-2 hrs 0.1-0.2 mg/L
MB2-FA 764-945, (182 aa) -17.51 SB 3-6 hrs 2 mg/L
MB2-IF2 1337-1606, (270 aa) +5.26 LB or SB 1 hr 0.5-1.0 mg/L
a Position is based on the translation initiation methionine (1).
b Calculated at neutral pH
c LB, Luria Broth; SB, Super Broth. Media were made according to instructions in Sambrook et al.,[39].
d Expressed as amount of purified protein per volume of IPTG-induced culture
e Combined length of MB2-A+MB-2B+MB2-CMalaria Journal 2009, 8:235 http://www.malariajournal.com/content/8/1/235
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Table 3: Individual antibody responses to MB2 recombinant peptides of the B domain as determined by immunoblot analysis.
MB2-Aa MB2-Ba MB2-Ca
Volunteer serum
Volunteer #1 (protected) - b ++ b -/+ b
Volunteer #3 (protected) - ++ -/+
Volunteer #5 (protected) - ++ -/+
Volunteer #7 (protected) - ++ -/+
WRAIR #1 (protected) - ++ -/+
WRAIR #4 (not protected) - - -
WRAIR #5 (not protected) - - -
WRAIR #6 (not protected) - - -
Kenyan serum
Smear negative
MB2-Aa MB2-Ba MB2-Ca Age
(yrs)
CSP
AUd
TRAP
AUd
c KU 036 - ++ + 29 1.77 2.35
KU 071 - ++ +++ 18 1.24 2.08
KU 081 - + ++ 34 1.01 1.23
KU 069 - + ++ 18 0.55 1.31
KU 079 - -/+ ++ 80 1.0 2.63
KU 083 - -/+ +++ 45 4.28 4.80
KU 163 - ++ -/+ 18 1.75 1.46
KU 202 - - + 30 2.22 2.22
KU 205 - -/+ -/+ 44 1.81 1.17
Smear positive, asymptomatic
KU 118 - - - 23 1.94 1.85
KU 044 - + - 6 0.75 0.79
KU 048 - - + 6 0.61 0.62
KU 076 - - -/+ 6 1.29 0.72
KU 001 - ++ ++ 2 1.11 1.43
KU 049 - - - 6 1.64 0.66
KU 025 - - - 6 0.42 0.26
Smear positive, symptomatic
KU 064 - - - 27 1.38 2.40
KU 070 - + - 18 1.41 1.59
KU 157 - + +++ 20 1.64 1.37
KU 158 - + ++ 26 ND ND
KU 165 - - - 26 0.34 0.10
KU 172 - -/+ ++ 22 ND ND
KU 199 - + -/+ 19 ND ND
KU 203 - - -/+ 30 1.34 1.0
KU 207 - - + 19 ND ND
KU 234 - + -/+ 42 ND ND
KU 162 - + +++ 6 ND ND
KU 062 - - - 6 0.87 1.85
KU 161 - - -/+ 7 0.67 0.88
KU 041 - - -/+ 6 1.62 0.71
KU 037 - ++ -/+ 60 1.36 1.52
KU 072 - -/+ -/+ 24 0.59 1.0
KU 075 - + ++ 32 0.72 1.35
KU 080 - -/+ + 34 0.87 1.50
KU 088 - - - 70 1.01 0.57
KU 145 - + + 40 3.01 2.56
KU 155 - - ++ 37 0.53 0.38
KU 174 - + + 22 2.27 1.90
KU 183 - -/+ ++ 23 0.30 0.36
KU 067 - - + 6 1.90 2.95
KU 084 - ++ + 2 0.40 1.277
a Peptides are described in Figure 1. b - no detectable band, -/+ weak band but visible, + weak band, ++ moderate to strong band and +++ intense band on 
western blot. c KU= serum obtained from individuals living in Kenya d AU = arbitrary units, see Methods for definition. CSP = circumsporozoite protein; 
TRAP = thrombospondin related adhesive protein.
ND = not determinedMalaria Journal 2009, 8:235 http://www.malariajournal.com/content/8/1/235
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the number of repeat units, two out of eleven isolates
(Ven-IS9 and PNG Muz37) have 7 versus 6 repeats (Figure
2). No other polymorphisms were detected outside the
repeat region
In vitro inhibition of sporozoite invasion assay
The results showed that the IgG against the non-repeat-
containing MB2-B peptide has the most potent inhibitory
effect, 57% (Table 4). In contrast, the IgG against the
repeat-containing peptide, MB2-C, exhibited only 18%
inhibition. Moreover the IgG fraction against another
repeat-containing but non-antigenic peptide, MB2-FA,
conferred 33% inhibition.
Discussion
MB2 is a novel sporozoite surface protein, that is present
at several stages of the parasite lifecycle albeit in different
sub-cellular locations as described earlier [20]. It is com-
posed of three distinct domains, an amino terminal basic
domain, a central acidic domain and a carboxyl terminal
GTP binding domain as shown in the schematic Figure
1A. The surface localization of MB2 at the sporozoite stage
provides a potential target for an antibody mediated
response. Within the MB2 basic domain three overlap-
ping polypeptides, and one non-overlapping polypeptide
spanning between the basic and acidic domains, and three
more polypeptides covering the remainder of the acidic
domain and a C-terminal polypeptide were initially gen-
erated as GST-His-tagged sandwich fusions and used to
immunize rabbits. The immune rabbit IgG was used in an
inhibition of sporozoite invasion (ISI) assay. Antibodies
against MB2 B inhibited sporozoite invasion (57%),
whilst antibodies directed against MB-FA and MB2-C
inhibited poorly (33% and 18% respectively) as shown in
Amino acid sequence alignment showing the size polymorphism in the repeat region of the MB2 gene from different laboratory  strains and field isolates Figure 2
Amino acid sequence alignment showing the size polymorphism in the repeat region of the MB2 gene from 
different laboratory strains and field isolates. Amino acid positions 211 to 264 make up the repeat domain. Identical 
amino acids outside the repeat domain are not shown. Field isolates were surveyed from India, Venezuela (Ven), Thailand 
(Thai) and Papua New Guinea (PNG).
MB2NF54 LNSKKNDNTLNSKKNDNTLNSKKNDNT---------LNSKNNNNSLNSKNNNNSLNSKKSNNS
MB2Dd2 LNSKKNDNTLNSKKNDNTLNSKKNDNT---------LNSKNNNNSLNSKNNNNSLNSKKSNNS
MB2FCB LNSKKNDNTLNSKKNDNTLNSKKNDNT---------LNSKNNNNSLNSKNNNNSLNSKKSNNS
MB2FCR3 LNSKKNDNTLNSKKNDNTLNSKKNDNT---------LNSKNNNNSLNSKNNNNSLNSKKSNNS
India-FasC LNSKKNDNTLNSKKNDNTLNSKKNDNT---------LNSKNNNNSLNSKNNNNSLNSKKSNNS
India-FJBD2 LNSKKNDNTLNSKKNDNTLNSKKNDNT---------LNSKNNNNSLNSKNNNNSLNSKKSNNS
India-FJBD4-3/13 LNSKKNDNTLNSKKNDNTLNSKKNDNT---------LNSKNNNNSLNSKNNNNSLNSKKSNNS
Ven-AHZ30C LNSKKNDNTLNSKKNDNTLNSKKNDNT---------LNSKNNNNSLNSKNNNNSLNSKKSNNS
Ven-AHZ45C LNSKKNDNTLNSKKNDNTLNSKKNDNT---------LNSKNNNNSLNSKNNNNSLNSKKSNNS
Ven-IS9 LNSKKNDNTLNSKKNDNTLNSKKNDNTLNSKKNDNTLNSKNNNNSLNSKNNNNSLNSKKSNNS
Ven-M96D LNSKKNDNTLNSKKNDNTLNSKKNDNT---------LNSKNNNNSLNSKNNNNSLNSKKSNNS
Thai-420 LNSKKNDNTLNSKKNDNTLNSKKNDNT---------LNSKNNNNSLNSKNNNNSLNSKKSNNS
Thai-421 LNSKKNDNTLNSKKNDNTLNSKKNDNT---------LNSKNNNNSLNSKNNNNSLNSKKSNNS
Thai-423 LNSKKNDNTLNSKKNDNTLNSKKNDNT---------LNSKNNNNSLNSKNNNNSLNSKKSNNS
PNG-Muz37 LNSKKNDNTLNSKKNDNTLNSKKNDNTLNSKKNDNTLNSKNNNNSLNSKNNNNSLNSKKSNNS
Table 4: Evaluation of in vitro inhibition of sporozoite invasion (ISI) by rabbit antibodies against different regions of MB2
IgG SPOROZOITES/WELL MEAN ± SDa % INHIBITIONb
MB2-B
PRE-IMMUNE 522, 514, 593 543 ± 35 0
MB2-B 205, 251, 238 231 ± 19 57%
MB2-Cc
PRE-IMMUNE 216, 312, 240 256 ± 40 0
MB2-C 252, 177, 198 209 ± 31 18%
MB2-FAc
PRE-IMMUNE 472, 485, 438 465 ± 20 0
MB2-FA 263, 354, 306 307 ± 37 33%
mAb NFS1 11, 9, 6 8 ± 2 97%
MEMdControl 280, 350, 325 318 ± 29 0
a SD, standard deviation
b Inhibition expressed as % relative to pre-immune control culture (0%), and it was calculated as follows: 100 × [1 - (mean number of invaded 
sporozoites in test culture/mean number of invaded sporozoites in control culture)]. Pre-immune antibodies used as negative control.
c These peptides contain amino acid repeat motifs.
dMEM Minimal essential medium.Malaria Journal 2009, 8:235 http://www.malariajournal.com/content/8/1/235
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Table 4, suggesting that antibodies directed against this
non-repeat region may be important in protection against
infection. All five protected volunteers produced anti-
MB2 antibodies preferentially against the non-repeat
MB2-B region, and the ISI assay showed that rabbit anti-
MB2-B antibodies are more effective than antibodies
against other regions of MB2 at blocking sporozoite inva-
sion of hepatocytes. It may be speculated that anti-MB2-B
antibodies may contribute to the overall protective sterile
immunity acquired by non-replicating metabolically-
active sporozoite immunized volunteers. Immunoblot
analyses of plasma from individuals in an area of highly
seasonal transmission during a period of high transmis-
sion also demonstrated higher frequencies of anti-MB2-B
antibodies among individuals who were not infected with
P. falciparum as compared to those who were. However,
these individuals also had higher levels of anti-MB2-C
antibodies. In this preliminary limited study the sera were
obtained at a single point in time and we cannot know
whether either type of antibodies were associated with
protection from infection in this population. It is very
likely that the inoculum of infection in these individuals
was much lower than that of the irradiated sporozoite-
infected individuals. The data suggest that individuals
with intermittent natural P. falciparum exposure have B
cell responses that include regions of the MB-2 antigen
recognized by those protected individuals exposed to irra-
diated sporozoites. The qualitative and quantitative anti-
body responses to the area most strongly associated with
protection in immunized volunteers (MB-2B) may be
impaired in individuals in areas of seasonal transmission.
There was no clear relationship between malaria symp-
toms and presence of antibodies to a specific region (MB-
2B or MB-2C), but since presence of antibodies was
assessed at the time of disease, we can conclude only that
symptomatic and asymptomatic individuals in this area
are able to mount antibody responses to MB-2B and MB-
2C. Further studies are required to characterize these
responses in individuals who reside in areas of high-level,
year-round  P. falciparum transmission, and prospective
studies required to assess the association of these antibod-
ies with protection from infection and disease in endemic
areas.
One of the striking observations is that protected volun-
teers were able to recognize preferentially the non-repeat
MB2-B and to a lesser degree the repeat-including MB2-C
and -D regions that most naturally exposed persons in
malaria-endemic areas recognize. The significance of such
a qualitative difference in the antibody response is diffi-
cult to assess due to the limited sample size. It is known
that at the optimal radiation dosage required to induce
sterile immunity, the weakened sporozoite is not able to
develop completely in the hepatocytes [30,31]. Since the
stage-dependent cellular localization of MB2 is accompa-
nied by differential proteolytic processing [20], it may be
that MB2 is aberrantly processed and is misdirected onto
the surface of infected cells. Alternatively, B-cell response
may be due to the exposure 'dose' of sporozoites. Pro-
tected volunteers received hundreds to more than a thou-
sand bites of infected and irradiated mosquitoes in order
to acquire sterile immunity [13]. In contrast, in malaria
endemic countries, exposed individuals receive on aver-
age less than 200 infective bites per year [32], and in the
highland area of Kenya where the endemic serum samples
were collected, the number of infective bites is likely to be
much lower than this [33]. It is possible that, the quanti-
tative difference of inoculated sporozoites is responsible
for the difference observed in antibody recognition
against MB2 between protected volunteers and persons
living in endemic countries. However antibodies against
MB2-B were more frequent in those without parasitaemia
than those with parasitaemia in the malaria endemic area,
consistent with the findings in the protected versus unpro-
tected volunteers.
The antigenic regions in the basic domain of MB2 were
analyzed for potential amino acid polymorphisms. The
nucleotide sequence of the MB2 gene was determined for
field isolates obtained from different malaria-endemic
regions of the world. It was expected that samples derived
from non-overlapping locales would provide the greatest
opportunity to detect sequence variation in MB2. The
analysis of the primary structure of amplified MB2 DNA
fragments from different isolates of P. falciparum showed
that antigenic variation is unlikely to be a factor contrib-
uting to the different antibody response against MB2.
Except for variation in the number of repeat units, the
antigenic region in the B domain of MB2 is absolutely
conserved among laboratory strains and field isolates col-
lected from different parts of the world as shown in Figure
2. The amino acid sequence conservation may reflect a
functional constraint of the B domain since it is not only
exposed on the surface of the sporozoite but also translo-
cated into the nucleus of blood-stage parasites[20]. In our
in vitro ISI study, antibodies to this conserved, antigenic
region of MB2 can inhibit sporozoite invasion of hepato-
cytes. If these antibodies play a role in protective immu-
nity in vivo, the finding that the antigenic region of MB2 is
highly conserved suggests that it might make a good target
for immune attack by antibodies since most, if not all, P.
falciparum sporozoites would be recognized.
The Plasmodium parasite is genetically complex, and based
on the malaria genome sequencing projects [34] may have
5,000-6,000 genes. Its antigenic composition also is
expected to be complex. Thus, the challenge in designing
effective malaria vaccine(s) is to define the immunogenic
molecules that are essential and the methods to present
them properly to the immune system to induce theMalaria Journal 2009, 8:235 http://www.malariajournal.com/content/8/1/235
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desired immune responses that protected the volunteers
experimentally immunized with the non-replicating met-
abolically-active sporozoite vaccine. The MB2 protein
possesses a number of molecular and immunogenic prop-
erties that indicate it is an intriguing candidate to comple-
ment current vaccine studies. Studies have shown that
immunity to malaria also is mediated, at least partly, by
cellular immune mechanisms [35]. In endemic areas,
cytotoxic T lymphocytes (CTLs) from exposed individuals
recognize epitopes in a number of pre-erythrocytic anti-
gens of P. falciparum, and indirect evidence indicates that
these CTLs may play a role in protective immunity [36-
38]. Since MB2 was shown to be present in multiple devel-
opmental stages including the hepatic stage that can be
recognized by CTLs, it will be important to obtain evi-
dence that MB2 also is recognized by CTLs from P. falci-
parum-exposed individuals. The variation in the nature
and strength of immune response observed in the
endemic plasma samples may also be due to host factors
such as MHC class I and II restriction. Further studies
across multiple populations are needed to assess the type
and strength of responses in individuals of differing
genetic backgrounds. It is anticipated that as more novel
parasite immunogens are characterized, the knowledge
gained from studying them will help bridge the gap
between recombinant and attenuated sporozoite vaccines.
The P. falciparum antigen MB2 is a multi-domain sporo-
zoite surface protein [20]. In this study denatured recom-
binant peptide fragments MB2 were probed with immune
plasma or sera resulting in the detection of antibodies
directed against linear epitopes. Immunoblot analyses
using serum of a volunteer protected by the exposure to
non-replicating metabolically active sporozoites (#5)
revealed that linear epitopes within the basic domain of
MB2 are recognized strongly, whilst the acidic domain is
recognized poorly. In comparison, plasma from a person
living in an endemic region (KU 162) contained antibod-
ies against linear epitopes within both basic and acidic
domains. Antibodies against linear epitopes within the
GTP binding domain were not detected in either set of
samples. Moreover, sera from all the protected volunteers
(non-replicating, metabolically-active sporozoite immu-
nized) contain antibodies against MB2. In contrast, no
anti-MB2 antibodies were detected in sera of non-pro-
tected (also non-replicating metabolically-active sporo-
zoite immunized) volunteers. Furthermore, antibodies
from the serum of protected volunteers recognized prefer-
entially the non-repeat-containing MB2-B peptide, while
the repeat-containing MB2-C peptide is recognized prefer-
entially by the antibodies in the plasma of persons living
in malaria-endemic areas. In addition, although the acidic
domain also contains two amino acid repeat regions [20],
serum from a protected volunteer showed minimal anti-
body reactivity against the acidic domain. In contrast, two
regions of the acidic domain, one of which contains
amino acid repeats, were recognized strongly by the anti-
bodies in the endemic plasma (MB2-D & MB2-E). These
qualitative results are interpreted to indicate that there
may be one or more B-cell epitopes encoded in the non-
repeat regions of MB2-B, that are more relevant to protec-
tive immunity than those encoded in the repeat regions.
The results of the inhibition of sporozoite invasion assay
suggest that antibodies directed against epitopes encoded
in the non-repeat region (MB2-B) possess greater anti-par-
asitic activities than antibodies against epitopes encoded
in the repeat-included region (MB2-C). The in vitro ISI
assay showed that anti-MB2-B antibodies are more effec-
tive than anti-MB2-FA and anti-MB2-C antibodies at
blocking sporozoites from invading the hepatocyte.
Although ~40% of the parasites are still able to enter
HepG2 cells, it is not known whether their intra-hepatic
development is affected. The change of the cellular loca-
tion of MB2 from the surface to the nucleus as the parasite
lifecycle progresses from the sporozoite stage to the eryth-
rocytic stage is consistent with the interpretation that it
may have a function in the development of the parasite
[20]. Thus, it is possible that anti-MB2 antibodies,
although they partially block invasion of the sporozoites,
they could also hinder the intra-hepatic development.
Conclusion
The multi-domain MB2 protein is a sporozoite surface
antigen identified on the human malaria parasite,Plasmo-
dium falciparum. Analysis of serum from eight human vol-
unteers that were immunized via the bites of P. falciparum
infected irradiated mosquitoes, revealed five that devel-
oped immunity and were completely protected against
subsequent challenge with non-irradiated parasite also
had detectable levels of antibody against MB2. In contrast,
in three volunteers not protected, anti-MB2 antibodies
were below the level of detection. Moreover, anti-MB2
antibodies were detected in the plasma of 83% of the indi-
viduals living in a malaria endemic area of Kenya (n = 41).
Antibodies from protected volunteers preferentially recog-
nized a non-repeat region of the basic domain of MB2,
whereas plasma from naturally-infected individuals had
antibodies that recognize regions of MB2 that contain a
repeat motif. Furthermore, rabbit polyclonal antibodies
targeting the non-repeat region of the basic domain con-
ferred greater inhibition of sporozoites entry into HepG2-
A16 cells in vitro relative to antibodies directed against the
repeat regions. Sequence analysis of eleven field isolates
and four laboratory strains showed that these antigenic
regions of the B domain of the MB2 gene are highly con-
served in parasites obtained from different parts of the
world. A preliminary analysis of the human humoral
response against MB2 indicates that it may be an addi-
tional conserved target for immune intervention at the
pre-erythrocytic stage of P. falciparum life cycle.Malaria Journal 2009, 8:235 http://www.malariajournal.com/content/8/1/235
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